Siteman Investment Program Karen Kharasch, Executive Director

Disclosure Information 2015 CCAF Annual Meeting I have no financial relationships to disclose.

SITEMAN INVESTMENT PROGRAM 40k / year from the CCSG We have significant philantrophy and multiple major events. Barnard Trust

Siteman Investment Program (SIP) 2009 – 2014 Profile 83 $12.4 million SIP awarded grants $ 39.2 million 71 Leveraged grants 107 7 Total of 71 subsequent grants 3:1 Our CCSG developmental fund support is $40,000 per year, which is significantly augmented by philanthropy assets to provide adequate pilot funding. Combined annual awards to SCC members from the SIP average just over $2 million to support and encourage collaborative pre-clinical, translational and innovative cancer-related projects. From 2009-2013, SCC has awarded a total of $10.9 million to 67 investigators representing all seven programs. Our faculty leveraged $34.7 million to date in direct costs in external funding including 21 NCI awards: $22 million (63% of total leveraged). Mechanisms require or encourage use of SRs and to promote inter-programmatic research, co-investigators from at least two different programs. The SIP has been highly successful in developing new collaborations between program members and allows investigators to generate preliminary data which can be used to leverage additional external, peer-reviewed funding. 32 45% 3 4% 36 51%

Evaluation of RFAs and Review Process Difficulties 5 annual scientific review committees Extreme difficulty finding reviewers Faculty feedback: Uncertain what the reviewers/Senior Leadership wants Transparency Consistency of announcement Competitive renewals for all 2 year awards

New SIP Model Streamline & Transparent The following current Siteman RFAs will now be incorporated into the new review model SCC Research Development Awards (RDA) Breast Cancer Program Career Development (CDA) Breast Research Development Awards Cancer Frontier Fund (CFF) ACS-IRG will be a sub-study section Devised by past chairs of our review committees, Assoc. Directors of Basic and translational sciences

Assumptions Total awards are dependent on philanthropy The number of awards and the award amount may increase or decrease each year dependent on SCC philanthropy Total awards are dependent on scientific merit The number of awards and the award amount may increase or decrease each year dependent on scientific merit of the applicants at each study section

Purpose Discovery, diagnosis, treatment and public health Create an agile study section model in order to provide pilot funding for SCC members in discovery, diagnosis, treatment and public health Discovery, diagnosis, treatment and public health New diagnostic tests, imaging technology, drug, vaccine, or other cancer therapy Accelerate discoveries to test and verify pioneering options Produce data that provide the basis for future applications (such as R01s, R21s, DOD, SPOREs, PPGs, etc.) or the opportunity for business creation and venture funding Catalyze discoveries by building bridges among disciplines and researchers in St. Louis (WU, WUSM, SLU and soon UMSL)

for 2 years (direct costs) Total award for 2 years (direct costs) # of awards  Cycle 1 Cycle 2 Announced January 1 July 1 Due date May 1 October 1 Start date Pre-R01 $400,000 2 Pre-SPORE/PPG $ 800,000 1 Multi-PI Pre-R01 Danforth/Consortium $ 200,000 Total awarded for 2 years $ 1,800,000 5 4 types of RFAs will be offered: Pre-R01 Program for WUSTL Medical School faculty and a Pre-R01 Program for SLU Consortium and Danforth Campus faculty Multi-PI Pre-R01 for all Siteman Cancer Center members Pre-SPORE/PPG program for all Siteman Cancer Center members

SIP Study Section Structure Representatives from all Programs 21 - 28 reviewers Recommended and assigned by each program leaders Rotating Chairs by program Internal competition reviews as required Ad hoc leadership: Associate Directors of Basic Science, Translation, Shared Resources and Executive Director

SIP Study Section Structure Rotation of Reviewers Each review cycle will have 14 of the 21 reviewers Ad hoc reviewers as required Reviewers will serve 3 year term Required to participate in 4 of the 6 reviews in the three year period Rotate off after 4 study sections Allows reviewers to take off a cycle to submit

Funds Allotment Review Funding Review Chairs of the Study Section Associate Directors of Basic, Translation Science and Shared Resources Executive Director VP BJH Foundation BJH Foundation Board member Pedal the Cause Executive Director Business Director

Budget and Scientific Review Business Director & staff have access to all Siteman SIP accounts Science Scientific progress is reported once a year. We can see accruals

www. siteman.wustl.edu